Stock Ratings / Consumer Staples / PETS / earnings

YI (42) RDGT (43) GRDN (77) CVS (61) ⌘ Pro Terminal →

PetMed Express Inc. (PETS) Next Earnings Date & Expected ±8% Move

$1.18 -0.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

PetMed Express Inc. (PETS) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $25.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PETS)Realized 20D OHLCV Swing Band: ±8%

NEXT EST. WINDOW: Dec 29, 2026 (~57 DAYS)

Historical OHLCV Volatility ±8% Swing Band

±$0.09 Expected Swing

MODEL EARNINGS SETUP GAUGE

PETS Quantitative Pre-Earnings Setup: 26/100

Trailing EPS: $4.25 • YoY Revenue Growth: -21.1%

Model Bullish Setup (26/100)Model Risk Weight (74/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2026-03-31	$179.0M	-$57.3M	-$33.0M	28.1%
FY 2024	2025-03-31	$227.0M	-$6.3M	-$395.0K	30.5%
FY 2023	2024-03-31	$274.1M	-$7.5M	$4.3M	28.1%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PETS)

✓Walkthrough of PETS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PETS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.32%▼ DESCENDING CHANNEL

2026-10-30O $1.17H $1.20L $1.17C $1.18VOL 42.3K

RES: $1.50SUP: $1.05SMA50: $1.48SMA200: $2.11

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PETS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PETS Butterfly Map → + Track PETS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -21.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PETS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PETS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PETS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PETS)

Consumer Staples Rank #143 of 146 ⚔️ YI vs PETS Full Matrix →

1. Head-to-Head Consumer Staples Peer Comparison (PETS vs. YI, RDGT, GRDN, CVS)

Industry: Retail-Drug Stores and Proprietary Stores (5 Tracked Issuers)

Across 146 tracked Consumer Staples securities in the Roarable RQD universe, PetMed Express Inc. (PETS) ranks #143 by composite RQD confidence (26/100, grade E) and #117 by equity capitalization ($25.6M). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with PETS at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PETS ACTIVE PetMed Express Inc.	E	26/100	—	28.1%	-35.0%	-0.84%	$25.6M	Benchmark Subject
YI 111 Inc.	D-	42/100	—	5.8%	-20.5%	+0.34%	$26.2M	/yi-vs-pets →
RDGT Ridgetech Inc.	D-	43/100	—	3.6%	—	-2.45%	$3.0M	/rdgt-vs-pets →
GRDN Guardian Pharmacy Services Inc. (Class A)	B+	77/100	52.1x	20.2%	37.7%	+0.30%	$2.56B	/grdn-vs-pets →
CVS CVS Health Corporation	C-	61/100	65.3x	45.0%	2.6%	+0.42%	$115.53B	/cvs-vs-pets →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001040130

In its most recent audited fiscal period (FY2025, filed 2026-03-31), PetMed Express Inc. (PETS) reported GAAP revenue of $179.0M (-21.1% vs. FY2024 revenue of $227.0M , and -34.7% cumulative change since FY2023) , GAAP net income of -$57.3M, operating cash flow of -$28.4M, and free cash flow of -$33.0M (-8256.7% YoY). On the balance sheet, PETS closed FY2025 with $88.0M in total assets against $0 in total debt (Altman Z-Score: 0.24, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$179.0M	-$57.3M	-$28.4M	-$33.0M	$88.0M	—
FY2024 (FY)	2025-03-31	$227.0M	-$6.3M	$4.7M	-$395.0K	$144.8M	—
FY2023 (FY)	2024-03-31	$274.1M	-$7.5M	$4.3M	$4.3M	—	—

3. PETS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PETS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, PetMed Express Inc. (NASDAQ: PETS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.18 (-0.84% 1D, market cap $25.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 146 tracked Consumer Staples issuers, PETS ranks #143 in composite RQD confidence.

How does PETS compare to YI and RDGT in the Consumer Staples sector?

Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), PETS carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -35.0%. By comparison, YI (111 Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M) and RDGT (Ridgetech Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PETS?

Per PETS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001040130), PetMed Express Inc. generated $179.0M in revenue (-21.1% YoY), -$57.3M in net income, and -$33.0M in free cash flow against $88.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PETS trading relative to its 50-day, 200-day, and 52-week technical levels?

PETS last traded at $1.18 (-0.84% on volume of 12,520 shares), positioning the stock -20.27% below its 50-day simple moving average ($1.48) and -44.08% below its 200-day simple moving average ($2.11). Across its 52-week range of $1.15 to $4.10, PETS sits at the 1.0% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.0% ($1.09 to $1.27).